Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients

•The efficacy of LCT in bone oligometastatic lung adenocarcinoma is controversial.•This study provided real-world treatment outcomes in bone oligometastatic patients.•The current findings suggested that additional LCT could bring survival benefits.•LCT plus EGFR-TKIs could be a better therapeutic option in these patients.